NCT00655265已完成4 期
A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, MultiCentre Study of Colesevelam as Add-on Therapy in Patients With Familial Hypercholesterolaemia
Genzyme, a Sanofi Company7 个研究点 分布在 5 个国家目标入组 86 人开始时间: 2007年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 86
- 试验地点
- 7
- 主要终点
- Relative reduction in LDL cholesterol
研究概览
简要总结
This study is designed to assess whether colesevelam given as third line treatment added to a maximal tolerated and stable dose of a statin and ezetimibe is able to further decrease the level of LDL cholesterol in a safe and efficient manner in difficult to treat Familial Hypercholesterolaemia patients who are not at their target level of LDL cholesterol.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a clinical diagnosis of Familial Hypercholesterolaemia defined as EITHER a.Presence of a documented LDL-receptor mutation OR b. History of untreated LDL-cholesterol level above the 95th percentile for sex and age in combination with documentation of at least one of the following: i.Presence of typical tendon xanthomas in the patient or first degree relative. ii. An LDL-cholesterol level above the 95th percentile for age and sex in a first degree relative. iii. Proven coronary artery disease in the patient or in a first degree relative under the age of
- •Patients must have provided and undergone lifestyle changes for more than 6 months at the time of Screening
- •Patients must have been treated for at least 3 consecutive months preceding the Screening visit with a lipid lowering treatment regimen consisting of maximal tolerated combination of a statin with ezetimibe and are still above their target for LDL cholesterol being 2.5 mmol/L (100 mg/dL)
- •Patients must be committed to following the protocol requirements as evidence by written informed consent
- •Patients should be comfortable with swallowing 3 placebo tablets
排除标准
- •Patients with a known allergy to any of the components used in colesevelam or placebo or any other medications like statin or ezetimibe required for participation in this study
- •Patients with a bowel or biliary obstruction
- •Patients with secondary causes of hypercholesterolaemia, e.g., dysproteinaemia, hypothyroidism, nephrotic syndrome (defined as proteinuria >2 g/L), obstructive liver disease, other pharmacological therapies, alcoholism
- •Patients with triglyceride level of > 3.4 mmol/L
- •Patients with dysphagia, swallowing disorders, severe gastrointestinal motility disorders, inflammatory bowel disease, or major gastrointestinal tract surgery
- •Patients have undergone LDL-apheresis within one year prior to the screening visit and/or need to undergo LDL-apheresis
- •Patients with active liver disease or unexplained persistent elevations in transaminases
- •Patients on fenofibrates or on concomitant cholestyramine as this will affect the area under the curve (AUC) of ezetimibe
- •Patients with poorly-controlled diabetes (i.e., HbA1c>9% at Screening)
- •Patients with clinically significant (CS) abnormal haematology, renal, or other laboratory parameters that could be the result of an underlying malignancy or systemic infection as judged by the investigator
- •Patients with a heart transplant, concurrent congestive heart failure (NYHA Class 3 or 4), life-threatening ventricular arrhythmias, unstable angina, recent myocardial infarction within the past 6 months prior to screening, or patients undergoing haemodialysis, or with active disease who may not be healthy enough to successfully complete all protocol requirements
- •Fertile women who are pregnant, nursing or using either no or an inadequate form of contraception taking into account the recommendations for adequate intake of oral contraceptives as outlined in concomitant medication section
- •Patients with a recent history of alcoholism or drug abuse, or sever emotional behavioural or psychiatric problems who may not be able to adequately comply with the requirements of the study or who may be unable to consent
- •Patients receiving experimental medications or participating in another study using an experimental drug or procedure within 30 days prior to signing informed consent
研究组 & 干预措施
Colesevelam hydrochloride film-coated tablets
Experimental
干预措施: Colesevelam hydrochloride film-coated tablets (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Relative reduction in LDL cholesterol
时间窗: Between baseline and 6 weeks DB treatment
次要结局
- Relative reduction in LDL cholesterol(Between Baseline and week 12 DB treatment)
- Relative reduction in HDL, total cholesterol, ApoA1,ApoB,ApoB/ApoA1ratio, triglycerides(Between Baseline and week 6 and week 12 DB treatment)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT01539512Gilead Sciences220
已完成
3 期
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux DiseaseNon-erosive Reflux DiseaseNCT05587322Braintree Laboratories800
已完成
2 期
Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in JapanArthritis, RheumatoidNCT00603512Pfizer140
已完成
3 期
MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT00854035Ono Pharmaceutical Co. Ltd266
已完成
3 期
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's DiseaseCrohn's DiseaseNCT01541579Tigenix S.A.U.278